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Abstract Pleural effusion (PE) represents the leading cause
of dasatinib (DAS) discontinuation. However, the pathogenic
mechanism of this adverse event (AE) is unknown and its
management unclear.We investigated if a DAS dose reduction
after the first PE would prevent the recurrence of this AE. We
retrospectively collected data on all the cases of PE in CML-
chronic phase (CP) DAS-treated patients from November
2005 to February 2017 in 21 Italian hematological centers.
We identified 196 cases of PE in a series of 853 CML-CP
DAS-treated patients (incidence 23.0%). DAS starting dose
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was 100 mg/day in 70.4% of patients, less than 100 mg/day in
14.3%, and more than 100 mg/day in the remaining cases.
Median time from DAS start to PE was 16.6 months. At first
PE development, 28.6% of patients were in MMR, and 37.8%
in deep molecular response (DMR). DAS was temporary
interrupted in 71.9% of cases, with a dose reduction in
59.2%. Recurrence was observed in 59.4% of the cases.
Treatment was definitively discontinued due to PE in 29.1%
of the cases. Interestingly, among patients whose DAS dosage
was reduced, 59.5% experienced PE recurrence. DAS dose
reduction after the first episode of PE did not prevent recur-
rence of this AE. Therefore, once a MMR or a DMR is
achieved, different strategies of DAS dose management can
be proposed prior to the development of PE, such as daily
dose reduction or, as an alternative option, an on/off treatment
with a weekend drug holiday.
Keywords Chronic myeloid leukemia . Dasatinib . Pleural
effusion .Molecular response . Dose reduction
Introduction
The development of small molecule tyrosine kinase inhibitors
(TKIs) has dramatically changed chronic myeloid leukemia
(CML) patients’ prognosis as they potently interfere with the
interaction between the BCR-ABL1 fusion protein and adeno-
sine triphosphate (ATP), so blocking the proliferation of the
malignant clone [1]. This Btargeted^ approach significantly
altered the natural history of CML and improved 10-year
overall survival from less than 20 to 80–90% [2, 3].
Among the actually available TKIs, dasatinib is a dual
BCR-ABL1 and SRC inhibitor approved for the first- and
second-line treatment of CML with a distinct toxicity profile
that includes pleural effusion (PE), whose most common
symptoms are dry cough, fatigue, decreased exercise toler-
ance, chest pain, and dyspnea [4, 5].
Several risk factors for dasatinib-related PE have been al-
ready reported. In particular, previous or concomitant cardiac
disease and hypertension seem to be the most common pre-
disposing conditions [4, 5]. Also, twice daily scheduling [4],
advanced CML phases [6–9], hypercholesterolemia, a previ-
ous history of autoimmune disorders and skin rashes experi-
enced during imatinib therapy have been identified as addi-
tional risk factors [5]. Older age is also associated with PE
[10], and in patients older than 65 years [11], the presence of
concomitant pulmonary disease, the initial daily dose of
dasatinib (140 vs 100 mg) [12, 13], and a higher comorbidity
index [14] have all been reported to be associated with PE.
In addition, actually there are no data clearly supporting a
correlation between PE and pulmonary arterial hypertension
(PAH). In particular, in a study by Shah et al. [15] describing
41 cases of dasatinib-induced PAH confirmed by means of
right-heart catheterization, even though 28 patients (68%)
had a synchronous PE at the time of PAH onset, the former
was not a typical feature of PAH.
What important, PE does not seem to impair the ability of
CML patients to obtain a response; indeed, as reported by
Porkka et al., the odds ratio for response in patients with PE
compared with those without was 2.1 (95% CI, 1.3 to 3.5) in
terms of complete cytogenetic response (CCyR), indicating
that PE may be associated with an increased likelihood of
response to dasatinib [10]. The same observation is also re-
ported in the DASISION trial, where 96% of the patients with
PE achieved a CCyR, 82% a major molecular response
(MMR), and 50% a molecular response 4.5 (MR4.5). All
these data suggest the importance of an adequate PE manage-
ment, including dose interruptions, dose reductions, and phar-
macologic interventions [11].
As PE represents the leading cause of dasatinib permanent
interruption, mainly because of the high rate of recurrence
[16], we conducted a retrospective, observational study with
the aim of investigating if an appropriate dasatinib dose reduc-
tion after the first PE could have prevented the recurrence of
this AE. The study was conducted in a large multicenter
Italian series of CML patients treated with dasatinib in the
real-life setting, so excluding any possible selection bias as
those related to data which derived from clinical trials enroll-
ing strictly selected patients.
Methods
In the frame of this observational study, 21 Italian hematolog-
ical centers were asked to retrospectively collect data on all the
cases of CML-chronic phase (CP) patients who developed a
PE during dasatinib therapy fromNovember 2005 to February
2017.
All the following data were collected at CML diagnosis:
sociodemographic variables, type and number of concomitant
diseases which were defined and assessed according to the
Charlson comorbidity index (CCI) [17], and concomitant
treatments. Concerning CML-specific data, risk scores,
BCR-ABL1 transcript type, previous therapies other than
TKIs, dosage of any prior TKI, and initial dose of dasatinib
were recorded. From 2006 on, monitoring and responses
followed the current European LeukemiaNet recommenda-
tions [18–20].
Hematological and extra-hematological toxicity grade was
revised according to the Common Terminology Criteria for
Adverse Events (CTC-AE) v4.03 [21]. In particular, PE has
been classified using a grading scale from 1 to 5, with 1 as
asymptomatic (no intervention indicated) and 5 as death asso-
ciated with this AE.
For what concerns PE variables, we collected patients’ age
at first PE, time from dasatinib start to first PE, concomitant
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pericardial effusion, therapeutic interventions, including
dasatinib dose modulation, response to dasatinib at first PE,
relapse and time from the first episode to subsequent one, rate
of and reason for dasatinib permanent discontinuation.
Results
Globally, we identified 196 cases of PE in a series of 853
dasatinib-treated CML-CP patients (incidence 23.0%), with
a median follow-up from diagnosis of 7.9 years (range, 0.1–
26.0). Male to female ratio was approximately 2:1, with a
median age at diagnosis of 60 years (range, 25–86).
Main clinical variables of our series at diagnosis are sum-
marized in Table 1. Notably, among comorbidities, hyperten-
sion was the most frequently reported (39.8% of the patients),
whereas pulmonary and autoimmune disorders, which are
both well-known risk factors for PE, were present in only
11.7 and 6.6% of the cases, respectively.
Thirty-four (17.4%) patients were front-line treated with
dasatinib, while the remaining 162 (82.6%) received dasatinib
in second- or subsequent lines. In detail, the latter patients
were all previously treated with imatinib for a median time
of 38.0 months (range, 0.1–151). Main reasons for imatinib
discontinuation were primary or secondary resistance in
75.3% and intolerance in 24.7% of cases (Table 2).
Dasatinib starting dose was 100 mg/day in 138 (70.4%)
patients, less than 100 mg/day in 28 (14.3%), and more than
100 mg/day in the remaining cases.
As reported in Table 3, median time from dasatinib start to
first PE was 16.6 months (range, 0.3–109), with 73.5% of
cases occurring within the first 3 years. No significant differ-
ence was detectable between patients who were in the first-
line setting and in subsequent lines of treatment, but the num-
ber of patients who were in first-line was small.
According to CT-CAE, PE severity was graded as 1 in
17.9%, 2 in 62.7%, and 3 in 19.4% of the cases; no grade 4
PE was observed. In addition, concomitant pericardial effu-
sion was reported in 17.3% of the patients, the great majority
of which were of grade 1 or 2. Furthermore, we identified only
five cases of PAH, which account for a global incidence of
2.5% among the entire population.
At the time of first PE, 33.6% of the patients were in less
than MMR, 28.6% were in MMR, and 37.8% were in DMR.
Dasatinib was temporary interrupted in 71.9% of cases,
with a subsequent dose reduction in 59.2% of the cases
(Table 4). Recurrence was observed in 59.4% of the cases,
with a median time from the first episode to the subsequent
one of 8 months (range, 0.5–70). Treatment was definitively
discontinued due to PE in 29.1% of the cases, with only a
slight difference between the first- (23.5%) and the second-
or subsequent line setting (30.2%). A reduction of dasatinib
dose after the first PE did not prevent a recurrence that was
reported in 59.5% of such cases.
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Table 2 Patients’ treatment
Patients (N = 196)
Previous interferon, n (%) 34 (17.3)
Previous imatinib, n (%) 162 (82.6)
Time of treatment with imatinib (months),
median (range)
38.0 (0.1–150.9)
Reason for switching to dasatinib, n (%)
Primary resistance to imatinib 65 (40.1)
Loss of response 43 (26.6)
Intolerance to imatinib 40 (24.7)
Progression to advanced phases 14 (8.6)
Starting daily dose of dasatinib (mg), n (%)
< 100 28 (14.3)
100 138 (70.4)
140 30 (15.3)
Table 1 Patients’ characteristics at diagnosis
Patients (N = 196)
Male/female 125/71
Age at diagnosis (years), median (range) 60.2 (24.9–86.2)
CCI at diagnosis, n (%)
0 105 (53.6)
1 44 (22.5)
2 23 (11.7)
3 15 (7.6)
≥ 4 9 (4.6)
Cardiovascular comorbidities, n (%) 43 (21.9)
Pulmonary comorbidities, n (%) 23 (11.7)
Autoimmune disorders, n (%) 13 (6.6)
Hypertension, n (%) 78 (39.8)
Hypercholesterolemia, n (%) 35 (17.9)
Diabetes, n (%) 36 (18.4)
Sokal risk, n (%)
Low risk 49 (25)
Intermediate risk 83 (42.3)
High risk 44 (22.5)
NA 20 (10.2)
Transcript type, n (%)
b3a2 98 (50)
b2a2 66 (33.7)
b3a2/b2a2 9 (4.6)
p190 7 (3.6)
b3a2/p190 1 (0.5)
NA 15 (7.6)
CCI Charlson comorbidity index, NA not available
Concerning first PE clinical management, the most fre-
quent treatment was represented by diuretics (86.7%), follow-
ed by steroids (74.5%), whereas in 15.3% of cases a
thoracentesis was required.
Globally, 30 patients died during the follow-up, but only
20% of all the registered deaths were defined as CML-related.
In detail, 13 patients died for cardiovascular events, four for
second malignancies, three for cerebrovascular events, three
for infectious complications, and the remaining patients for
senectus.
Discussion
Although the pathogenetic mechanism of dasatinib-related PE
is not clearly understood, it has been speculated that it may be
of inflammatory nature, based on reports of high lymphocyte
counts, often of a NK cell phenotype, in pleural fluid and
tissue [4, 5, 10, 22]. Alternatively, dasatinib-related PE may
occur through potent inhibition of the PDGFR-β, leading to a
reduction in interstitial fluid pressure, or inhibition of SRC-
family kinases, resulting in vascular permeability changes [4].
However, the exact pathogenic mechanism of this AE still
remains actually unknown.
The risk of PE exists with most of the TKIs currently ap-
proved for both first- and second-line CML-CP treatment (ima-
tinib, dasatinib, nilotinib, and bosutinib), as it is a class-specific
side effect, but it is much higher with dasatinib. Indeed, as
reported in the DASISION trial, the incidence of PE was 28%
as compared with 0.8% in the imatinib group, being the median
time to first PE of 10 months, with most cases (89%) occurring
more than 8 weeks from the treatment start [11]. In patients
resistant or intolerant to imatinib, PE incidence ranges from
14 to 39% [12], with a median time to appearance of 5–
11 months [10, 13], even if it can be delayed until 3 years [23].
However, most of the cases were mild or moderate, with
grade 3/4 reported in 3% of all events [11, 12]. Furthermore,
low rates of dasatinib discontinuation due to this AE, either
during the first year of treatment [8], or in the follow-up
(total discontinuation rate of 6% in the DASISION and
7% among patients treated with the approved 100 mg once
daily dose in the CA180-034 studies) are described [11, 12].
Nevertheless, as reported in the most recent European
LeukemiaNet recommendation for the management of
AEs during TKIs treatment, recurrence of PE occurs in
roughly 70% of the cases [16], thus representing the leading
cause of dasatinib definitive interruption.
With the aim of investigating if a dasatinib dose reduction
after the first PE can prevent the recurrence of this AE, we
retrospectively collected all the cases of PE which developed
during dasatinib therapy in CML-CP patients regularly
followed in 21 Italian hematological centers.
Comparing our data to those reported in the literature, we
identified a MMR and a DMR rate at the median time of PE
superior to that of both first- and second-line dasatinib-treated
CML population (globally 51% at 12 months in the
DASISION and 37% at 24 months in the CA180-034 study)
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Table 3 Patients’ characteristics at pleural effusion
Patients (N = 196)
Time from starting dasatinib to pleural
effusion (months), median (range)
16.6 (0.3–109.0)
First-line patients (n = 34), median
(range)
16.6 (0.3–53.8)
Second- or subsequent lines
(n = 162), median
(range)
16.6 (0.6–109.0)
< 1 year, n (%) 77 (39.3)
1–2 years, n (%) 44 (22.5)
2–3 years, n (%) 23 (11.7)
3–4 years, n (%) 20 (10.2)
4–5 years, n (%) 18 (9.2)
> 5 years, n (%) 14 (7.1)
Age at pleural effusion (years),
median (range)
66.9 (29.9–90.0)
Pleural effusion grade, n (%)
Grade 1 35 (17.9)
Grade 2 123 (62.7)
Grade 3 38 (19.4)
Concomitant pericardial effusion,
n (%)
34 (17.3)
Response to dasatinib at pleural effusion,
n (%)
Too early 6 (3.1)
None 3 (1.5)
CHR 4 (2)
MCyR 1 (0.5)
PCyR 5 (2.5)
CCyR 21 (10.7)
Less than MMR 19 (9.7)
MMR 56 (28.6)
DMR 74 (37.8)
NA 7 (3.6)
Total recurrent pleural effusion, n (%) 104 (59.4)
Recurrent pleural effusion after
dasatinib dose reduction (n = 116),
n (%)
69 (59.5)
Time from first pleural effusion to
subsequent episodes (months),
median (range)
7.9 (0.5–69.9)
Recurrent pleural effusion grade, n (%)
Grade 1 7 (6.7)
Grade 2 79 (76)
Grade 3 18 (17.3)
CHR complete hematological response, MCyR major cytogenetic
response, PCyR partial cytogenetic response,CCyR complete cytogenetic
response, MMR major molecular response, DMR deep molecular
response, NA not available
[11, 12], also distinguishing between imatinib-intolerant and
resistant cases.
Furthermore, it has to be highlighted a high PE recurrence
rate (59.5%) also after dasatinib dose reduction.
Interestingly, in our case series, we noted that PE was ap-
proximately twice as common in men as in women. In addi-
tion, differently fromwhat it has been reported in the literature
so far, the majority of the cases (about 73.5%) happened with-
in the first 3 years of therapy and then its frequency gradually
decreased. Furthermore, we observed a very low incidence of
PAH in our population, thus supporting that PAH represents
an infrequent complications of PE.
Concerning the severity of this AE, the majority of cases
weremild ormoderate, probably because of an early diagnosis
and treatment during clinical monitoring, with the aim of
preventing long-term or definitive dasatinib interruption.
Therefore, despite the limits of a retrospective study, this
report represents a description of PE outside clinical trials, in
the real-life setting, thus avoiding all significant selection bias.
The great majority of the patients were receiving dasatinib in
second or a subsequent phase, so that the data cannot be ex-
tended to patients receiving dasatinib in first-line.
Dasatinib dose reduction after the first episode of PE did
not prevent the recurrence of this AE (Table 3). Since many
patients developed the first PE when they were already in
MMR or even in DMR, it is possible that a reduction of the
dose prior to the occurrence of a PE, in the patients who have
already achieved a MMR or a DMR, can help to reduce the
rate of PE, overall.
Accordingly, different strategies of dasatinib dose reduc-
tion can be proposed, such as daily dose reduction (e.g., from
100 to 80 mg/day or from 80 to 50 mg/day) or, as an alterna-
tive option, an on/off treatment with a weekend drug holiday.
The latter strategy has been demonstrated to reduce PE as well
as hematologic toxicity, thus keeping the response level
achieved by conventional continuous dosing and so allowing
continuation of dasatinib treatment for patients suffering from
AEs [24].
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